Advertisement

Journal of Medical Toxicology

, Volume 15, Issue 4, pp 228–254 | Cite as

The Toxicology Investigators Consortium Case Registry-the 2018 Annual Report

  • Meghan B. SpyresEmail author
  • Lynn A. Farrugia
  • A. Min Kang
  • Diane P. Calello
  • Sharan L. Campleman
  • Anthony Pizon
  • Timothy Wiegand
  • Louise Kao
  • Brad D. Riley
  • Shao Li
  • Paul M. Wax
  • Jeffery Brent
  • On behalf of the Toxicology Investigators Consortium (ToxIC) Study Group
Original Article

Abstract

The Toxicology Investigators Consortium (ToxIC) Registry was established by the American College of Medical Toxicology (ACMT) in 2010. The Registry collects data from participating sites with the agreement that all bedside medical toxicology consultation will be entered. The objective of this ninth annual report is to summarize the Registry’s 2018 data and activity with its additional 7043 cases. Cases were identified for inclusion in this report by a query of the ToxIC database for any case entered from 1 January to 31 December 2018. Detailed data was collected from these cases and aggregated to provide information which included demographics, reason for medical toxicology evaluation, agent and agent class, clinical signs and symptoms, treatments and antidotes administered, mortality, and whether life support was withdrawn. A total of 51.5% of cases were female, 48% were male, and 0.6% transgender. Non-opioid analgesics were the most commonly reported agent class, followed by antidepressants and opioids. Acetaminophen was once again the most common agent reported. There were 106 fatalities, comprising 1.5% of all registry cases. Major trends in demographics and exposure characteristics remained similar to past years’ reports. Sub-analyses were conducted to describe exposures in elderly patients, addiction consultation practices, and risk factors for bupropion-induced seizures. The launch of the ToxIC Qualified Clinical Data Registry (TQCDR) is also described.

Keywords

Poisoning Overdose Surveillance Epidemiology Medical Toxicology 

Notes

Acknowledgments

Toxicology Investigators Consortium (ToxIC) Study Group Collaborators:

Beauchamp GA, Beuhler MC, Boyle KL, Cannon RD, Carey JL, Carpenter J, Chenoweth JA, Colby DK, Eisenga BH, Fisher E, Ford JB, Fox LM, Ganetsky M, Gorodetsky R, Greene SC, Griswold MK, Harding SA, Hendrickson RG, Horowitz BZ, Hoyte C, Jacob J, Judge BS, Kazzi Z, Kerns WP 2nd, Kim T, Koons A, Leikin JB, Levine M, Liss DB, Marino R, McKay CA, McKeever RG, Meadors K, Moore E, Mullins ME, Nacca N, Nelson ME, Porter L, Riley BD, Ruha AM, Santos C, Schult R, Schwarz ES, Scoccimarro A, Seifert SA, Shafer S, Shah KR, Smolinske SC, Spyres M, Tortora L, Vearrier DJ, Warrick BJ, Weiss S, Wolk BJ, Yanta J.

We also wish to thank study coordinators Andrea Ramirez, D Hopkins, DA Gonzalez, Julie Licata, K Hart, Love Wilson, MD Cook, Melissa Vandenberg, PM Beuhler, T Falter and Tammy Phan.

Funding Information

The Toxicology Investigators Consortium received funding from the US National Institute of Drug Abuse 1RO1DA037317-02, and data sharing contracts with the U.S. Food and Drug Administration and BTG International, Inc. (North America).

Compliance with Ethical Standards

Conflict of Interest

None.

Previous presentation of data

This data has not been previously presented.

Supplementary material

13181_2019_736_MOESM1_ESM.docx (485 kb)
ESM 1 (DOCX 484 kb)

References

  1. 1.
    Farrugia LA, Rhyee SH, Campleman SL, et al. The Toxicology Investigators Consortium Case Registry-the 2017 Annual Report. J Med Toxicol. 2018;14(3):182–211.CrossRefGoogle Scholar
  2. 2.
    Farrugia LA, Rhyee SH, Calello DP, et al. The Toxicology Investigators Consortium Case Registry-the 2016 Experience. J Med Toxicol. 2017;13(3):203–26.CrossRefGoogle Scholar
  3. 3.
    Rhyee SH, Farrugia L, Wiegand T, et al. The toxicology investigators consortium case registry-the 2013 experience. J Med Toxicol. 2014;10(4):342–59.CrossRefGoogle Scholar
  4. 4.
    Rhyee SH, Farrugia L, Campleman SL, Wax PM, Brent J, Toxicology Investigators C. The Toxicology Investigators Consortium Case Registry--the 2014 Experience. J Med Toxicol. 2015;11(4):388–409.CrossRefGoogle Scholar
  5. 5.
    Farrugia LA, Rhyee SH, Campleman SL, et al. The Toxicology Investigators Consortium Case Registry-the 2015 Experience. J Med Toxicol. 2016;12(3):224–47.CrossRefGoogle Scholar
  6. 6.
    Wiegand TJ, Wax PM, Schwartz T, et al. The Toxicology Investigators Consortium Case Registry--the 2011 experience. J Med Toxicol. 2012;8(4):360–77.CrossRefGoogle Scholar
  7. 7.
    Wiegand T, Wax P, Smith E, Hart K, Brent J. The Toxicology Investigators Consortium Case Registry--the 2012 experience. J Med Toxicol. 2013;9(4):380–404.CrossRefGoogle Scholar
  8. 8.
    Brent J, Wax PM, Schwartz T, et al. The Toxicology Investigators Consortium Case Registry-the 2010 experience. J Med Toxicol. 2011;7(4):266–76.CrossRefGoogle Scholar
  9. 9.
    Spencer MR, Warner M, Bastian BA, Trinidad JP, Hedegaard H. Drug Overdose Deaths Involving Fentanyl, 2011-2016. Natl Vital Stat Rep. 2019;68:3):1–19.PubMedGoogle Scholar
  10. 10.
    Thomas AA, Von Derau K, Bradford MC, Moser E, Garrard A, Mazor S. Unintentional Pediatric Marijuana Exposures Prior to and After Legalization and Commercial Availability of Recreational Marijuana in Washington State. J Emerg Med. 2019;56(4):398–404.CrossRefGoogle Scholar
  11. 11.
    Ng PC, Banerji S, Graham J, Leonard J, Wang GS. Adolescent exposures to traditional and novel psychoactive drugs, reported to National Poison Data System (NPDS), 2007-2017. Drug Alcohol DependDrug Alcohol Depend. 2019;202:1–5.CrossRefGoogle Scholar
  12. 12.
    Kang AM. Substances Involved in Suicidal Poisonings in the United States. Suicide Life Threat Behav. 2018.Google Scholar
  13. 13.
    Finkelstein Y, Hutson JR, Wax PM, Brent J. Toxicology Investigators Consortium Case R. Toxico-surveillance of infant and toddler poisonings in the United States. J Med Toxicol. 2012;8(3):263–6.CrossRefGoogle Scholar

Copyright information

© American College of Medical Toxicology 2019

Authors and Affiliations

  • Meghan B. Spyres
    • 1
    Email author
  • Lynn A. Farrugia
    • 2
  • A. Min Kang
    • 3
    • 4
  • Diane P. Calello
    • 5
  • Sharan L. Campleman
    • 6
  • Anthony Pizon
    • 7
  • Timothy Wiegand
    • 8
  • Louise Kao
    • 9
  • Brad D. Riley
    • 10
  • Shao Li
    • 6
  • Paul M. Wax
    • 11
  • Jeffery Brent
    • 12
  • On behalf of the Toxicology Investigators Consortium (ToxIC) Study Group
  1. 1.Department of Emergency Medicine, Division of Medical ToxicologyUniversity of Southern CaliforniaLos AngelesUSA
  2. 2.Hartford Hospital and University of Connecticut School of MedicineHartfordUSA
  3. 3.Departments of Medicine and Child HealthUniversity of Arizona College of Medicine–PhoenixPhoenixUSA
  4. 4.Department of Medical ToxicologyBanner–University Medical CenterPhoenixUSA
  5. 5.New Jersey Medical School, RutgersThe State University of New JerseyNewarkUSA
  6. 6.American College of Medical ToxicologyPhoenixUSA
  7. 7.University of Pittsburgh School of Medicine and University of Pittsburgh Medical CenterPittsburghUSA
  8. 8.University of Rochester Medical Center and Strong Memorial HospitalRochesterUSA
  9. 9.Indiana university school of medicineIndianapolisUSA
  10. 10.Michigan State University College of Human MedicineGrand RapidsUSA
  11. 11.University of Texas Southwestern Medical SchoolDallasUSA
  12. 12.University of Colorado School of MedicineAuroraUSA

Personalised recommendations